Bristol Myers Squibb (BMS)

Scottish Medicines Consortium (SMC) accepts Camzyos▼(mavacamten) for use on the NHS as an adjunct treatment option for adults with symptomatic obstructive hypertrophic cardiomyopathy

Mavacamten has been accepted for use within NHS Scotland for the treatment of symptomatic(New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy(HCM) in adult patients. HCM is the most common inherited heart condition, affecting 1 in 500 people in the UK. 8 April 2024 -- Middlesex, UK -- Bristol Myers Squibb (BMS)...

Scottish Medicines Consortium accepts Sotyktu(deucravacitinib) for NHS use in certain adults with moderate to severe plaque psoriasis

Deucravacitinib has been accepted by the Scottish Medicines Consortium (SMC) for use in Scotland for the treatment of adults with moderate to severe plaque psoriasis who are eligible for systemic therapies In Scotland, it is estimated that over 133,520 individuals suffer with psoriasis 11 December 2023 -- Uxbridge, Middlesex -- Bristol Myers Squibb (BMS) today...
ARC Uxbridge Sanderson Road New Denham Denham Buckinghamshire UB8 1DH

01895 523000